[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene

Oncogene volume 20, pages 3814–3823 (2001)Cite this article

Abstract

Loss of heterozygosity (LOH) allows the expression of recessive mutation in tumor suppressor genes (TSG). Therefore, on the basis of Knudson's ‘two-hit’ hypothesis for TSG inactivation, the detection of a high LOH frequency in a chromosomal region is considered critical for TSG localization. One of these LOH regions in breast cancer is 16q22.1, which has been suggested to reflect the involvement of E-cadherin (E-cad), a cell–cell adhesion molecule. To confirm the tumorigenic role of E-cad, 81 sporadic invasive ductal carcinomas (IDCs) of the breast were tested for the ‘two hits’ required to inactivate this gene. A high frequency (37.3%) of LOH was detected in 67 informative tumors, but no mutation was found. To examine the possibility that transcriptional mechanisms serve as the second hit in tumors with LOH, specific pathways, including genetic variant and hypermethylation at the promoter region and abnormal expression of positive (WT1) and negative (Snail) transcription factors, were identified. Of these, promoter hypermethylation and increased expression of Snail were found to be common (>35%), and to be strongly associated with reduced/negative E-cad expression (P<0.05). However, unexpectedly, a significantly negative association was found between the existence of LOH and promoter hypermethylation (P<0.05), which contradicts the ‘two-hit’ model. Instead, since they coexisted in a high frequency of tumors, hypermethylation may work in concert with increased Snail to inactivate E-cad expression. Given that E-cad is involved in diverse mechanisms, loss of which is beneficial for tumors to invade but may also trigger apoptosis, this study suggests that maintaining a reversible mechanism, either by controlling the gene at the transcriptional level or by retaining an intact allele subsequent to LOH, might be important for E-cad in IDC and may also be common in TSGs possessing diverse functions. These findings provide clues to explain why certain TSGs identified by LOH cannot fulfil the two-hit hypothesis.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, Garcia de Herreros A . 2000 Nat. Cell Biol. 2: 84–89

  • Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP . 1998 Adv. Cancer Res. 72: 141–186

  • Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJF, van de Vijver MJ, Cornelisse C, van Roy F . 1995 EMBO J. 14: 6107–6115

  • Berx G, Cleton-Jansen AM, Strumane K, de Leeuw WJF, Nollet F, van Roy F, Cornelisse C . 1996 Oncogene 13: 1919–1925

  • Bièche I, Lidereau R . 1995 Genes Chromosom. Cancer 14: 227–251

  • Bindels EMJ, Vermey M, van den Beemd R, Dinjens WNM, Van Der Kwast TH . 2000 Cancer Res. 60: 177–183

  • Brown MA . 1997 Adv. Genet. 36: 45–135

  • Bukholm IK, Nesland JM, Børresen-Dale AL . 2000 J. Pathol. 190: 15–19

  • Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA . 2000 Nat. Cell Biol. 2: 76–83

  • Chausovsky A, Bershadsky AD, Borisy GG . 2000 Nat. Cell Biol. 2: 797–804

  • Christofori G, Semb H . 1999 Trends Biomed. Sci. 24: 73–76

  • Day ML, Zhao X, Vallorosi CJ, Putzi M, Powell CT, Lin C, Day KC . 1999 J. Biol. Chem. 274: 9656–9664

  • Davidson B, Bemer A, Nesland JM, Risberg B, Bemer HS, Tropè CG, Kristensen GB, Bryne M, Flørenes VA . 2000 J. Pathol. 192: 460–469

  • Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J., Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG . 2000 J. Natl. Cancer Inst. 92: 564–569

  • Fabre A, McCann AH, O'Shea D, Broderick D, Keating G, Tobin B, Gorey T, Dervan PA . 1999 Hum. Pathol. 30: 661–665

  • Fearon ER . 1997 Science 278: 1043–1050

  • Fearon ER . 2000 J. Natl. Cancer Inst. 92: 515–517

  • Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ . 1998 Nature 396: 177–180

  • Gonzalgo ML, Bender CM, You EH, Glendening JM, Flores JF, Walker GJ, Hayward NK, Jones PA, Fountain JW . 1997 Cancer Res. 57: 5336–5347

  • Grady WM, Willis J, Guilford PJ, Dunbier AK, Toro TT, Lynch H, Wiesner G, Ferguson K, Eng C, Park JG, Kim SJ, Markowitz S . 2000 Nat. Genet. 26: 16–17

  • Graff JR, Herman JG, Myöhänen S, Baylin SB, Vertino PM . 1997 J. Biol. Chem. 272: 22322–22329

  • Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG . 2000 J. Biol. Chem. 275: 2727–2732

  • Guilford P . 1999 Mol. Med. Today 4: 172–177

  • Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE . 1998 Nature 392: 402–405

  • Handschuh G, Candidus S, Luber B, Reich U, Schott C, Oswald S, Becke H, Hutzler P, Birchmeier W, Hofler H, Becker KF . 1999 Oncogene 18: 4301–4312

  • Hajra KM, Ji X, Fearon ER . 1999 Oncogene 18: 7274–7279

  • Healey CS, Dunning AM, Teare MD, Chase D, Parker L, Burn J, Chang-Claude J, Mannermaa A, Kataja V, Huntsman DG, Pharoah PDP, Luben RN, Easton DF, Ponder BAJ . 2000 Nat. Genet. 26: 362–364

  • Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB . 1996 Proc. Natl. Acad. Sci. USA 93: 9821–9826

  • Hosono S, Gross I, English MA, Hajra KM, Fearon ER, Licht JD . 2000 J. Biol. Chem. 275: 10943–10953

  • Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY . 1999 Cancer Res. 59: 4870–4875

  • Ilyas M . 2000 J. Pathol. 190: 3–5

  • Ingvarsson S . 1999 Semin. Cancer Biol. 9: 277–288

  • Ji X, Woodard AS, Rimm DL, Fearon ER . 1997 Cell Growth Diff. 8: 773–778

  • Jones PA, Laird PW . 1999 Nat. Genet. 21: 163–167

  • Kantak SS, Kramer RH . 1998 J. Biol. Chem. 273: 16953–16961

  • Khoo US, Ozcelik H, Cheung AN, Chow LW, Ngan HY, Done SJ, Liang AC, Chan VW, Au GK, Ng WF, Poon CS, Leung YF, Loong F, Ip P, Chan GS, Andrulis IL, Lu J, Ho FC . 1999 Oncogene 18: 4643–4646

  • Knudson AG Jr . 1971 Proc. Natl. Acad. Sci. USA 68: 820–823

  • Ku WH, Liu IL, Yen MS, Chang Chien CC, Yue CT, Ma YY, Chang SF, Ng HT, Wu CW, Shen CY . 1997 Int. J. Cancer 72: 270–276

  • Kuismanen SA, Holmberg MT, Salovaara R, de la Chapelle A, Peltomäki P . 2000 Am. J. Pathol. 156: 1773–1779

  • Lasko D, Cavenee WK,, Nordenskjold M . 1991 Annu. Rev. Genet. 25: 281–314

  • Laux DE, Curran EM, Welshons WV, Lubahn DB, Huang TH . 1999 Br. Cancer Res. Treat. 56: 35–43

  • Li LC, Chui RM, Sasaki M, Nakajima K, Perinchery G, Au HC, Nojima D, Carroll P, Dahiya R . 2000 Cancer Res. 60: 873–876

  • Lindblom A, Rotstein S, Skoog L, Nordenskjöld M, Larsson C . 1993 Cancer Res. 53: 3707–3711

  • Lo YL, Yu JC, Huang CS, Tseng SL, Chang TM, Chang KJ, Wu CW, Shen CY . 1998 Int. J. Cancer 79: 580–587

  • Lou MA, Tseng SL, Chang SF, Yue CT, Chang BL, Chou CH, Yang SL, The BH, Wu CW, Shen CY . 1997 Br. J. Cancer 75: 746–751

  • Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK, Shen CY . 2000 Oncogene 19: 2739–2744

  • MacLeod K . 2000 Curr. Opin. Genet. Dev. 10: 81–93

  • Nass SJ, Herman JG, Gabrielson E, Iversen PW, Parl FF, Davidson NE, Graff JR . 2000 Cancer Res. 60: 4346–4348

  • Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G . 1998 Nature 392: 190–193

  • Semb H, Christofori G . 1998 Am. J. Hum. Genet. 63: 1588–1593

  • Shen CY, Yu JC, Lo YL, Kuo CH, Yue CT, Jou YS, Huang CS, Lung JC, Wu CW . 2000 Cancer Res. 60: 3884–3892

  • Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, Isola JJ . 1996 Am. J. Clin. Pathol. 105: 394–402

  • Silberstein GB, Van Horn K, Strickland P, Roberts Jr CT, Daniel CW . 1997 Proc. Natl. Acad. Sci. USA 94: 8132–8137

  • Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L . 1998 Nature 393: 229–234

  • Tan DSP, Potts HWW, Leong ACK, Gillett CE, Skilton D, Harris WH, Liebmann RD, Hanby AM . 1999 J. Pathol. 189: 20–27

  • Tseng SL, Yu JC, Yue CT, Chang SF, Chang TM, Wu CW, Shen CY . 1997 Genes Chromosom. Cancer 20: 377–382

  • Valcárcel J, Green MR . 1996 Trend Biomed. Sci. 21: 296–301

  • Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, Donehower LA . 1998 EMBO J. 17: 4657–4667

  • Woodcock DM, Linsenmeyer ME, Doherty JP, Warren WD . 1999 Br. J. Cancer 79: 251–256

  • Xu X, Brodie SG, Yang X, Im YH, Parks WT, Chen L, Zhou YX, Weinstein M, Kim SK, Deng CX . 2000 Oncogene 19: 1868–1874

  • Yang PS, Yang TL, Liu CL, Wu CW, Shen CY . 1997 Br. J. Cancer 75: 752–756

Download references

Acknowledgements

We are grateful to Drs Pei-Jer Chen, Young-Sun Lin, and Jiahn-Chun Wu for their comments. This study was supported by the Clinical Research Fund of the Institute of Biomedical Sciences, Academia Sinica.

Author information

Author notes

  1. Chun-Wen Cheng, Pei-Ei Wu and Jyh-Cherng Yu: C-W Cheng, P-E Wu and J-C Yu contributed equally to this work

Authors and Affiliations

  1. Institute of Biomedical Sciences, Academia Sinica, Taipei, 115, Taiwan

    Chun-Wen Cheng, Pei-Ei Wu, Cheng-Wen Wu & Chen-Yang Shen

  2. The Life Science Library, Academia Sinica, Taipei, 115, Taiwan

    Chen-Yang Shen

  3. Graduate Institute of Epidemiology, School of Public Health, National Taiwan University, Taipei, 100, Taiwan

    Pei-Ei Wu

  4. Department of Surgery, Tri-Service General Hospital, Taipei, 114, Taiwan

    Jyh-Cherng Yu

  5. Department of Surgery, National Taiwan University Hospital, Taipei, 100, Taiwan

    Chiun-Sheng Huang

  6. Department of Pathology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, 111, Taiwan

    Chung-Tai Yue

  7. National Health Research Institutes, Taipei, 115, Taiwan

    Cheng-Wen Wu

Authors
  1. Chun-Wen Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pei-Ei Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jyh-Cherng Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chiun-Sheng Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chung-Tai Yue
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cheng-Wen Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chen-Yang Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chen-Yang Shen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cheng, CW., Wu, PE., Yu, JC. et al. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene 20, 3814–3823 (2001). https://doi.org/10.1038/sj.onc.1204505

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204505

Keywords

This article is cited by

Search

Advanced search

Quick links